Bradley J. FikesContact Reporter
Hundreds of patients have died while taking a Parkinson’s disease drug from San Diego’s Acadia Pharmaceuticals, according to a story by CNN.
In addition, CNN said many other patients weren’t benefiting from the drug, meant to control Parkinson’s disease psychosis. The article gave as its source a report from the non-profit Institute for Safe Medication Practices. The report was issued in November.
Acadia replied to CNN with a statement indicating that deaths among Nuplazid patients were, if anything, lower than the average among those with Parkinson’s disease psychosis.
A total of more than 700 patients taking the drug, Nuplazid, have died in the most recent tally by the U.S. Food and Drug Administration, CNN said.
Acadia shares dropped 25 percent Monday morning after the story was published. Nuplazid, is Acadia’s flagship drug. It was approved by the FDA in April 2016.
Nuplazid was taken by 244 patients who died since the drug’s launch and March 2017, according to the Institute for Safe Medication Practices report. These are deaths that were reported to the FDA among the drug’s potential “adverse events,” the report stated.
Acadia shares traded at $16.10, a drop of $5.42, as of 10: 26 a.m. Pacific time Monday. At that price, Acadia still has a market value of more than $2 billion, making it one of the biggest biomedical companies in San Diego County.
http://www.orlandosentinel.com/sd-me-acadia-safety-parkinsons-nuplazid-20180409-story.html#nt=oft06a-7la1
No comments:
Post a Comment